SAN DIEGO – Endeavor BioMedicines, a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, announced that the company has dosed its first patient in a Phase 2 trial of taladegib (ENV-101) to treat idiopathic pulmonary fibrosis (IPF). Taladegib is a small-molecule inhibitor...
Latest News
SAN DIEGO, Calif. — Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced successful completion of its Phase 2a clinical trial evaluating the company’s lead investigational compound, ENV-101, in patients with idiopathic pulmonary fibrosis (IPF). ENV-101...
SAN DIEGO, Calif. — Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced that The Lancet Respiratory Medicine has published results from a Phase 2a trial evaluating the safety and efficacy of taladegib (ENV-101) in patients with idiopathic...
Northbrook, Ill. — Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug TCMCB07 (B07) to prevent weight loss in cancer patients undergoing chemotherapy. The trial, being conducted in partnership with...
New York, NY – Endometrial cancer — which develops in the lining of the uterus (womb) and is sometimes called uterine cancer — is on the rise in the U.S. In 1987, there were 35,000 cases annually. That number has nearly doubled in 2023 to more than 66,000 cases. Deaths from...
SAN DIEGO, Calif. – Endure Biotherapeutics, Inc. (Endure Bio®), a pioneer in engineered engraftable microbial therapeutics, today announced it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The funding will support the development of a...
BASEL, Switzerland and LINCOLNSHIRE, Illinois — Vaderis Therapeutics today announced that data from its randomized, double-blind, placebo-controlled, multi-center proof-of-concept study and long-term extension of engasertib (VAD044) in Hereditary Hemorrhagic Telangiectasia (HHT) have been published in The New England Journal of Medicine (NEJM). This peer-reviewed publication marks an important milestone following initial release of study...
DURHAM, N.C. — A team of physicians, neuroscientists and engineers at Duke University has demonstrated two new strategies that use deep brain stimulation to improve the symptoms of Parkinson’s disease. By simultaneously targeting two key brain structures and using a novel self-adjusting device, the team showed that they can efficiently...
PTC Therapeutics’ Upstaza, a gene therapy for an ultra-rare genetic disorder and the first to be directly infused in the brain, is one step closer to reaching patients in the U.K. The National Institute for Health and Care Excellence (NICE) has recommended the therapy to treat patients with aromatic L-amino acid...
SAN DIEGO – Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies and The Texas A&M University System (TAMUS), today announced that they have entered into a license agreement which grants Engrail worldwide exclusive rights to intellectual property around the use...